Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Dorothee Nashan
ScientificTracks Abstracts-Workshop: J Clin Exp Dermatol Res
High incidences of actinic keratoses, the pathophysiologically proven and accepted transition of AK into SCC and the resulting unacceptable mortality rate unify world-wide medical efforts in improving early diagnoses and therapies of AKs. A spectrum of efficient therapeutic options is available. Guidelines and recommendations from across Europe - Germany, Great Britain, France, Italy, and Spain �?? underline interest in the assessment, acceptance and use of therapeutic options, but also reveal diverse attitudes towards these aspects. Efforts to combat AKs include primary and secondary prevention. The evaluation of treatment includes a consideration of effectiveness, sustainability and tolerability of procedures, as well as response rates. An incredible number of publications concerning catchphrases like actinic keratoses, therapy, studies and response rate and spinalioma development complicate a survey. Useful up-dates, critical reviews and recommendations are continuously published. The number and grades of AKs, the size of the area treated, and in particular the duration of follow up are different, often making comparisons unbalanced. Cochrane based data analyses and meta-analyses confirm those difficulties whilst offering a ranking of standard interventions. Shouldn't we ask for a more normative procedure concerning the goals of our studies? Where is the common denominator in requirements? Besides personal expertise and equipment, the individual decision for the treatment of AKs should be based on the best possible evidence. Algorithms and increasing demand of sequential therapies will profit. All countries agree on the necessity of early treatment, and with the focus on point and field treatment, with increasing interest in long-term success, including in cases of field cancerisation. Implementation in daily practice and further requirements shall be discussed.
Dorothée Nashan is Professor and Head of Department of Dermatology, Klinikum Dortmund, Germany. She is specialist in dermato-oncology focus on melanoma, cutaneous lymphoma and palliative care. Her education included scientific work in biochemistry and immunology in reproductive medicine (Max Planck Society, Harvard Medical School), clinical education in the Departments of Dermatology, University of Münster and Fribourg. Continously publishing papers and serving as an editorial board member of repute she is engaged in the promotion and education of young colleagues inter alia in connection with the German Society of Dermatology.